WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 11, 2018--
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of therapeutics
using its proprietary mucus-penetrating particle (MPP) technology,
announced today that the underwriters of its previously announced public
offering have exercised in full their option to purchase an additional
1,125,000 shares of common stock at the public offering price of $8.25
per share, less underwriting discounts. After giving effect to the
option closing, the total number of shares sold by Kala in the offering
increased to 8,625,000 shares, which resulted in gross proceeds of $71.2
million, before deducting underwriting discounts and commissions and
estimated offering expenses payable by Kala.
J.P. Morgan, BofA Merrill Lynch and Jefferies acted as joint bookrunning
managers for the offering. Cantor Fitzgerald & Co. served as lead
manager for the offering, and Wedbush PacGrow and Oppenheimer & Co. Inc.
acted as co-managers for the offering.
The shares were offered by Kala pursuant to a shelf registration
statement (including a prospectus) that was previously filed with and
declared effective by the U.S. Securities and Exchange Commission
(“SEC”). Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained from: J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; BofA
Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email
or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Kala Pharmaceuticals
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary MPP technology,
with an initial focus on the treatment of eye diseases. Kala has applied
the MPP technology to a corticosteroid, LE, designed for ocular
applications, resulting in recently approved INVELTYS for the treatment
of inflammation and pain following ocular surgery and its lead product
candidate, KPI-121 0.25%, for the temporary relief of the signs and
symptoms of dry eye disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005832/en/
Source: Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc.